Abstract
The House and the Senate have now passed bills that aim to ensure the safety of the drug supply in the United States. It is now up to both houses of Congress to agree on a strong final version of the bill to send to the President. Editors Gregory Curfman, Stephen Morrissey, and Jeffrey Drazen suggest essential components they believe the final bill should contain.Congressman Edward Markey (D-MA) discusses drug safety, the public reporting of clinical trial results, the need for new authority for the FDA, and the reauthorization of the Prescription Drug User Fee Act.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
